News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
751,238 Results
Type
Article (44286)
Company Profile (311)
Press Release (706622)
Multimedia
Podcasts (130)
Webinars (22)
Section
Business (211181)
Career Advice (2117)
Deals (36817)
Drug Delivery (142)
Drug Development (83567)
Employer Resources (177)
FDA (16927)
Job Trends (15541)
News (357829)
Policy (34151)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2641)
Accelerated approval (47)
Adcomms (28)
Allergies (177)
Alliances (51589)
ALS (215)
Alzheimer's disease (1823)
Antibody-drug conjugate (ADC) (461)
Approvals (17313)
Artificial intelligence (692)
Autoimmune disease (297)
Automation (57)
Bankruptcy (373)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (228)
Biotechnology (184)
Bladder cancer (195)
Brain cancer (76)
Breast cancer (761)
Cancer (5913)
Cardiovascular disease (486)
Career advice (1803)
Career pathing (43)
CAR-T (336)
CDC (59)
Celiac Disease (3)
Cell therapy (917)
Cervical cancer (47)
Clinical research (72461)
Collaboration (2125)
Company closure (5)
Compensation (1412)
Complete response letters (88)
COVID-19 (2817)
CRISPR (114)
C-suite (1163)
Cystic fibrosis (157)
Data (7973)
Decentralized trials (3)
Denatured (38)
Depression (166)
Dermatology (86)
Diabetes (593)
Diagnostics (7018)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (330)
Drug pricing (220)
Drug shortages (34)
Duchenne muscular dystrophy (287)
Earnings (93859)
Editorial (69)
Employer branding (22)
Employer resources (156)
Events (122516)
Executive appointments (1113)
FDA (20710)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (34)
Funding (1746)
Gene editing (241)
Generative AI (59)
Gene therapy (749)
GLP-1 (1106)
Government (4878)
Grass and pollen (7)
Guidances (409)
Healthcare (19193)
HIV (79)
Huntington's disease (57)
IgA nephropathy (99)
Immunology and inflammation (302)
Immuno-oncology (95)
Indications (195)
Infectious disease (3156)
Inflammatory bowel disease (224)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (295)
Interviews (330)
IPO (16946)
IRA (57)
Job creations (4075)
Job search strategy (1501)
JPM (65)
Kidney cancer (19)
Labor market (101)
Layoffs (593)
Leadership (41)
Legal (8427)
Liver cancer (101)
Longevity (33)
Lung cancer (773)
Lymphoma (432)
Machine learning (62)
Management (60)
Manufacturing (1080)
MASH (195)
Medical device (14020)
Medtech (14145)
Mergers & acquisitions (21124)
Metabolic disorders (1543)
mRNA (217)
Multiple sclerosis (188)
NASH (18)
Neurodegenerative disease (424)
Neuropsychiatric disorders (109)
Neuroscience (3366)
Neurotech (1)
NextGen: Class of 2026 (6648)
Non-profit (4579)
Now hiring (78)
Obesity (727)
Opinion (314)
Ovarian cancer (222)
Pain (274)
Pancreatic cancer (306)
Parkinson's disease (364)
Partnered (34)
Patents (604)
Patient recruitment (678)
Peanut (65)
People (61652)
Pharmaceutical (84)
Pharmacy benefit managers (34)
Phase 1 (22488)
Phase 2 (31892)
Phase 3 (23863)
Pipeline (8872)
Policy (337)
Postmarket research (2660)
Preclinical (9605)
Press Release (68)
Prostate cancer (306)
Psychedelics (57)
Radiopharmaceuticals (331)
Rare diseases (1117)
Real estate (6322)
Recruiting (73)
Regulatory (26331)
Reports (57)
Research institute (2464)
Resumes & cover letters (362)
Rett syndrome (39)
RNA editing (24)
RSV (88)
Schizophrenia (185)
Series A (294)
Series B (216)
Service/supplier (11)
Sickle cell disease (115)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (3790)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (99)
The Weekly (90)
Vaccines (1122)
Venture capital (110)
Weight loss (477)
Women's health (129)
Worklife (20)
Date
Today (173)
Last 7 days (832)
Last 30 days (3667)
Last 365 days (30711)
2026 (12911)
2025 (30680)
2024 (35760)
2023 (40627)
2022 (51798)
2021 (56327)
2020 (54791)
2019 (47397)
2018 (35768)
2017 (33137)
2016 (32662)
2015 (38614)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (808)
Alabama (93)
Alaska (7)
Arizona (355)
Arkansas (16)
Asia (42627)
Australia (6850)
California (13384)
Canada (3798)
China (1386)
Colorado (570)
Connecticut (582)
Delaware (414)
Europe (91782)
Florida (2001)
Georgia (426)
Hawaii (3)
Idaho (62)
Illinois (1071)
India (93)
Indiana (611)
Iowa (23)
Japan (553)
Kansas (133)
Kentucky (50)
Louisiana (43)
Maine (76)
Maryland (1603)
Massachusetts (9593)
Michigan (367)
Minnesota (725)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (144)
New Hampshire (84)
New Jersey (3517)
New Mexico (30)
New York (3508)
North Carolina (1717)
North Dakota (9)
Northern California (6701)
Ohio (401)
Oklahoma (24)
Oregon (46)
Pennsylvania (2697)
Puerto Rico (29)
Rhode Island (50)
South America (1181)
South Carolina (87)
South Dakota (2)
Southern California (5284)
Tennessee (212)
Texas (2136)
United States (47329)
Utah (399)
Vermont (1)
Virginia (338)
Washington D.C. (80)
Washington State (1071)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
751,238 Results for "biomarin pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop
BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth.
May 19, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal
With Ascendis Pharma entering the achondroplasia space last month and BridgeBio on deck, BioMarin faces competition. Adding to the pressure, the company suffered a setback Monday when it halted two studies of Voxzogo in other growth-related conditions following multiple cases of hip injuries in other trials of the drug.
March 16, 2026
·
2 min read
·
Heather McKenzie
Press Releases
BioMarin Completes Acquisition of Amicus Therapeutics
April 27, 2026
·
10 min read
Press Releases
BioMarin Announces Board Leadership Transition
April 22, 2026
·
4 min read
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
BioMarin Reports First Quarter 2026 Financial and Operating Results
May 4, 2026
·
22 min read
Press Releases
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
May 18, 2026
·
5 min read
Press Releases
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
April 27, 2026
·
1 min read
Press Releases
BioMarin to Participate in Four Upcoming Investor Conferences in March 2026
February 24, 2026
·
2 min read
Earnings
BioMarin Abandons Gene Therapy Roctavian, Cuts Revenue Guidance as Voxzogo Faces Competitors
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.
October 28, 2025
·
4 min read
·
Tristan Manalac
1 of 75,124
Next
